Corporate News

Receipt of deferred consideration

25 November 2022

Omega (AIM: ODX), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, announces that it has now received the £4.0m of deferred consideration relating to the sale of the CD4 business.

Accordingly, as of close of business on 24 November 2022, Omega held cash balances of £6.5m.

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014. 

Omega Diagnostics Group PLC  www.omegadx.com
Jag Grewal Chief Executive Officervia Walbrook PR
Chris Lea, Chief Financial Officer  
  
finnCap LtdTel: 020 7220 0500
Geoff Nash/Edward Whiley (Corporate Finance)  
Alice Lane/ Harriet Ward (ECM)  
  
Walbrook PR Limited Tel: 020 7933 8780 or [email protected]
Paul McManus Mob: 07980 541 893
Sam Allen Mob: 07502 558 258

About Omega Diagnostics Group PLC  
Omega (AIM: ODX) is a specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition. www.omegadx.com

Sign up for Investor Alerts